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Abstract: 
Herb–drug interaction predictions remain challenging. Physiologically based pharmacokinetic 
(PBPK) modeling was used to improve prediction accuracy of potential herb–drug interactions 
using the semipurified milk thistle preparation, silibinin, as an exemplar herbal product. 
Interactions between silibinin constituents and the probe substrates warfarin (CYP2C9) and 
midazolam (CYP3A) were simulated. A low silibinin dose (160 mg/day × 14 days) was predicted 
to increase midazolam area under the curve (AUC) by 1%, which was corroborated with external 
data; a higher dose (1,650 mg/day × 7 days) was predicted to increase midazolam and (S)-
warfarin AUC by 5% and 4%, respectively. A proof-of-concept clinical study confirmed minimal 
interaction between high-dose silibinin and both midazolam and (S)-warfarin (9 and 13% 
increase in AUC, respectively). Unexpectedly, (R)-warfarin AUC decreased (by 15%), but this is 
unlikely to be clinically important. Application of this PBPK modeling framework to other herb–
drug interactions could facilitate development of guidelines for quantitative prediction of 
clinically relevant interactions. 
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Article: 
Herbal products represent an ever-increasing component of Western pharmacotherapy due in 
part to the perception that “natural” equates with safety. Current regulatory oversight of herbal 
products in many Western countries, including the United States, does not include evaluation of 
drug interaction liability prior to marketing. Consequently, systematic approaches for 
quantitative prediction of both the magnitude and likelihood of herb–drug interactions are 
nonexistent. 
Drug interaction liability assessment of herbal products is more challenging than for 
conventional drugs because unlike most drug products, herbal products typically are mixtures of 
bioactive constituents that vary substantially between preparations.1,2,3 Compounding this 
complexity is the often scant knowledge of specific causative constituents or systemic exposure 
of such constituents. Due to incomplete absorption and extensive presystemic clearance, herbal 
product constituents may reach sufficient concentrations in the intestine and liver to inhibit only 
first-pass extraction of sensitive substrates.4 Consequently, traditional (static) prediction 
approaches frequently do not translate to the clinical setting for herb–drug interactions. 
Recent drug–drug interaction guidelines suggest dynamic modeling and simulation approaches to 
predict complex interactions.5,6 Extension of this approach to herb–drug interactions is a logical 
step to facilitate prospective evaluation of these interactions. As with drug–drug 
interactions,7,8 physiologically based pharmacokinetic (PBPK) modeling may be used to 
improve in vitro to in vivoextrapolation of herb–drug interactions. Well-characterized herbal 
products are needed to develop a quantitative framework. 
Milk thistle preparations are top-ten selling herbal products in the United States.9The crude 
extract, silymarin, contains at least seven flavonolignans and one flavonoid.10 The semipurified 
extract, silibinin, contains roughly a 1:1 mixture of the flavonolignans silybin A and silybin B 
and represents an exemplar herbal product for initial model development. First, silybin A and 
silybin B have been purified in quantities sufficient to recover requisite in 
vitro parameters.11,12Second, in vitro studies have demonstrated both reversible and mechanism-
based inhibition of the key drug metabolizing enzymes CYP2C913,14,15 and 
CYP3A4.13,14,16 Third, in vitro to in vivo extrapolation has been inconsistent.17,18,19 Based on 
these observations, the objective of this work was to advance the mechanistic understanding of 
this herb–drug interaction using PBPK modeling and simulation with warfarin and midazolam as 
probe substrates. The models were evaluated through a proof-of-concept clinical study in healthy 
volunteers. Results could help develop guidelines for prospective evaluation of herb–drug 
interaction liability. 
Results 
Modeling and simulation 
PBPK model generation and initial evaluation. Simulated probe substrate concentrations closely 
approximated previously published concentration–time profiles for both warfarin20 and 
midazolam21 under baseline conditions (data not shown). Model-predicted primary endpoints 
(area under the curve (AUC) and Cmaxfor (S)-warfarin and midazolam) were within the 
prespecified criterion (30%) for acceptable model performance (Table 1). 
Table 1 - Comparison of previously published and model-predicted pharmacokinetic 
outcomes. 
  
Prediction of silibinin–drug interaction magnitude. Simulations of a previously reported milk 
thistle-midazolam interaction, assuming reversible CYP3A inhibition solely due to silybin A and 
silybin B, demonstrated negligible changes in the midazolam concentration–time profile (Figure 
1). The milk thistle product tested, silymarin, contained 100 mg of silybin A and 180 mg of 
silybin B and was administered daily for 14 days.18 Simulations assuming mechanism-based 
CYP3A inhibition predicted a 30% and 60% increase in midazolam Cmax and AUC, respectively; 
increases of 6% and 3% in midazolam Cmax and AUC, respectively, were reported18 (Figure 1). 
 
Figure 1. Mean concentration–time profile (0–6 hours) of midazolam in 19 healthy volunteers 
following an 8 mg oral midazolam dose given alone (open symbols) or following a 14-day 
treatment with milk thistle product (solid symbols).18 Lines denote physiologically based 
pharmacokinetic model simulations of the midazolam concentration–time profile when given 
alone (black) or with milk thistle (green). The dotted green line denotes incorporation of 
reversible inhibition of CYP3A, whereas the dashed green line denotes incorporation of 
mechanism-based inhibition of CYP3A. Symbols and error bars denote observed means and 
SDs, respectively, and were obtained from ref. 18. 
Simulations of the silibinin–warfarin interaction with a higher dose of silibinin (1,650 mg/day, or 
720 mg silybin A plus 930 mg silybin B/day; see below), assuming reversible CYP2C9 inhibition 
only, predicted negligible changes (<5%) in all pharmacokinetic outcomes (Figure 2a; Table 2). 
Simulations of the high-dose silibinin–midazolam interaction assuming reversible CYP3A 
inhibition predicted no change in midazolam t1/2 and ≤5% increase in both Cmax and AUC 
(Figure 2b;Table 2). Simulations assuming mechanism-based CYP3A inhibition predicted a 2-, 
5-, and 1.5-fold increase in Cmax, AUC, and t1/2, respectively (Table 2). 
 
Figure 2. Geometric mean concentration–time profile of (a) warfarin, (b) midazolam, and (c) 
silibinin in 12 healthy volunteers following a 10 mg oral dose of warfarin or 5 mg oral dose of 
midazolam given alone (open symbols) or following a 7-day treatment with silibinin (solid 
symbols). Lines in a and b denote physiologically based pharmacokinetic (PBPK) model 
simulations of the concentration–time profiles when the probe substrates were given alone 
(black) or with silibinin (green). Blue and orange lines in c denote PBPK model simulations of 
the concentration–time profiles of silybin A and silybin B, respectively. Symbols and error bars 
denote observed geometric means and upper limits of the 90% confidence interval, respectively. 
Table 2 - Comparison of proof-of-concept clinical study outcomes to physiologically based 
pharmacokinetic model predictions. 
 
 
Proof-of-concept clinical evaluation 
Silibinin content in test product. A single lot (#304090) of Siliphos capsules, labeled to contain 
60 mg silibinin, was selected. The capsules were overfilled consistently, containing 
69.1 ± 4.28 mg silibinin represented as 30.3 ± 1.88 mg silybin A and 38.9 ± 2.39 mg silybin B. 
The capsules also contained minor amounts of the regioisomers isosilybin A (1.55 ± 0.09 mg) 
and isosilybin B (0.94 ± 0.06 mg). 
Study subjects. All enrolled subjects completed the study (Supplementary Table S2). The study 
drugs and silibinin generally were well tolerated. One subject experienced mild gastrointestinal 
upset following the first dose of silibinin. The effect was deemed likely to be drug related by the 
study physician but was transient and did not limit the subject’s continued participation. During 
Clinical and Translational Research Center (CTRC) visits, four subjects (two in both phases) 
reported mild headaches attributed to caffeine withdrawal. No international normalized ratio 
elevations from baseline were observed following warfarin administration. 
CYP2C9 genotyping. All enrolled subjects consented to genotyping. Ten subjects were 
homozygous for the reference CYP2C9*1 allele. Two subjects carried one copy of the reference 
allele and either the CYP2C9*2 or CYP2C9*3 allele. 
Effects of high-dose silibinin on warfarin and midazolam pharmacokinetics. The effects of high-
dose silibinin (1,650 mg/day) were compared to baseline oral pharmacokinetics of warfarin and 
midazolam. Due to the reported mechanism-based inhibition of CYP3A in vitro,14,16 silibinin was 
administered three times daily for 6 days prior to administration of the probe substrates. Silibinin 
constituents were not expected to accumulate during the administration period due to short 
reported half-lives (<4 hours).22 One subject demonstrated poor goodness-of-fit statistics for 
the t1/2 of both warfarin enantiomers in both phases (R2 < 0.85). Accordingly, data from this 
subject were excluded from analysis of AUC0–48 andt1/2. 
Warfarin enantiomers were absorbed rapidly during both study phases, with 
median tmax occurring at 1.25 and 1.5 hours for (R)- and (S)-warfarin, respectively (Figure 2a). 
Coadministration with silibinin did not alter median (S)-warfarin tmax but delayed median (R)-
warfarin tmax by 15 minutes. Relative to control (baseline), silibinin decreased (R)-warfarin 
geometric mean Cmax by 17% (Figure 3a; Table 2) and AUC0–48 by 15% (Figure 3b; Table 2). 
Silibinin decreased geometric mean (S)-warfarin Cmax by 2% (Figure 3c; Table 2). Geometric 
mean AUC0–48 of (S)-warfarin increased by 13% (Figure 3d; Table 2), with three subjects lying 
outside the predefined no effect range (0.75–1.33). The 90% confidence intervals for the (S)-
warfarin primary endpoints (Cmax and AUC) lay within the predefined no effect range (Table 2). 
 
Figure 3. Effects of silibinin (1,650 mg/day for 7 days) on (a,c,e) Cmax and (b,d,f) AUC of (a,b) 
(R)-warfarin, (c,d) (S)-warfarin, and (e,f) midazolam in 12 healthy volunteers following oral 
administration of warfarin (10 mg) and midazolam (5 mg). Open symbols connected by solid 
lines denote individual values. Solid symbols connected by dashed lines denote geometric 
means. 
The rapid absorption of midazolam was unaltered by coadministration with silibinin, with 
median tmax occurring at 0.5 hours (Figure 2b). Relative to control, silibinin increased 
midazolam geometric mean Cmax by 20% (Figure 3e; Table 2) and AUC0–inf by 9% (Figure 
3f; Table 2). Except for one subject (2.3-fold increase), treatment/control ratios of AUC0–inf lay 
within the predefined no effect range (Figure 3f). The 90% confidence interval for midazolam 
treatment/control ratio ofCmax extended above, whereas that of AUC0–inf lay within, the 
predefined no effect range (Table 2). 
The sampling strategy was not optimized for recovery of silybin A and silybin B 
pharmacokinetic outcomes; as such, these outcomes were interpreted for qualitative rather than 
quantitative purposes. The median tmax of silybin A and silybin B following the initial 
administration of silibinin (3 and 3.5 hours, respectively) nearly coincided with the second 
administration of silibinin (Figure 2c). Geometric mean Cmax for silybin A was more than double 
that for silybin B (Table 2). Geometric mean t1/2 of both silybin A and silybin B was ~5 hours 
(Table 2). 
DISCUSSION 
Although herbal product usage continues to increase, current regulatory guidelines in several 
Western countries do not request premarket evaluation of herb–drug interaction liability. 
Investigations into such liabilities are fraught with inconsistent results due to the lack of a 
standard system for evaluation, high compositional variation between herbal products, and 
uncertainty about causative constituents. Unlike conventional drug products, the relative 
composition of herbal products may vary substantially depending on weather conditions, product 
collection and storage methods, and processing procedures.4 Accurate predictions of herb–drug 
interaction liability require not only identification and quantification of causative constituents, 
but also measures of exposure in organs with metabolic capability. Silibinin was selected as an 
exemplar herbal product due to a well-characterized composition, availability of inhibitory 
kinetic parameters from individual constituents, and disparate impact of milk thistle products on 
victim drug pharmacokinetics in previous clinical studies.17,18,19 A PBPK modeling and 
simulation approach was used to address the challenges inherent to investigation of herb–drug 
interaction liability. 
Warfarin is a widely used oral anticoagulant with a narrow therapeutic window. Warfarin is 
associated with a notoriously complicated pharmacotherapy due in part to myriad drugs and 
herbal products that alter the metabolism or anticoagulant activity of warfarin. As the clearance 
of the more pharmacologically active (S)-enantiomer is mediated primarily by CYP2C9, 
inhibition of this enzyme can lead to increased risk of bleeding. Silymarin was shown previously 
to increase systemic exposure to the CYP2C9/3A substrate losartan,19 prompting evaluation of 
the interaction potential between milk thistle and warfarin. Of the milk thistle constituents whose 
CYP2C9 interaction liability has been evaluated in vitro, silybin A and silybin B were the most 
potent.15 These observations led to the selection of silibinin, which consists primarily of these 
two constituents, for clinical evaluation. 
Relative to control, silibinin unexpectedly decreased both the geometric meanCmax and AUC0–
last of (R)-warfarin. Clinical manifestation of the previously reported CYP1A2 induction by a 
milk thistle extract23 is consistent with this decrease in exposure. In contrast to the doubling of 
losartan exposure following administration of silymarin, high-dose silibinin did not increase 
geometric mean (S)-warfarin exposure to a clinically relevant extent. However, increases above 
33% were observed in three subjects, indicating that the CYP2C9 interaction potential of 
silibinin cannot be disregarded completely. Consistent with the expected decrease in (S)-warfarin 
clearance, the subject carrying the reduced functionCYP2C9*3 allele demonstrated prolonged 
warfarin exposure, which was not captured in the 48-hour sampling window. As such, the AUC 
and t1/2 for this subject were excluded from analysis. 
Modeling and simulation of the silibinin–warfarin interaction demonstrated that the rapid 
clearance of the silibinin constituents precluded marked inhibition of warfarin clearance. 
Sensitivity analysis of this interaction potential demonstrated that 10-fold increases in silybin A 
or silybin B inhibition potency (reversible Ki) would lead to roughly 15% increases in (S)-
warfarin AUC (Supplementary Figure S1). Extensive intestinal and hepatic conjugation of 
silybin A and silybin B followed by rapid elimination likely would limit the interaction potential 
to first-pass clearance of sensitive substrates. Warfarin is not sensitive to first-pass elimination 
and is cleared only upon subsequent passages through the liver, at which time any reversible 
inhibition of CYP2C9 by silybin A and silybin B would be abated. In contrast, losartan has a low 
bioavailability (33%) that is attributed, in part, to first-pass elimination.24 This observation, 
coupled with the differences in study population and herbal product tested, could explain the 
difference between the reported interaction with losartan19 and the lack of interaction with 
warfarin in the present study. Collectively, these observations suggest examination of other 
CYP2C9 substrates sensitive to first-pass elimination, such as fluvastatin, to understand fully the 
milk thistle-CYP2C9 interaction potential. 
Midazolam is a gold standard CYP3A probe substrate metabolized extensively by intestinal and 
hepatic enzymes. Inhibition of CYP3A at either site can increase systemic exposure to 
midazolam; inhibition of hepatic CYP3A also can increaset1/2. Milk thistle constituents, 
including silybin A and silybin B, have been shown to be reversible and mechanism-based 
inhibitors of CYP3A activity in both human liver microsomes and expressed enzyme 
systems.13,14,16 Previous clinical interaction studies with midazolam17,18 have demonstrated 
limited interaction liability with the milk thistle product silymarin, albeit the doses administered 
were not sufficient to determine the difference between reversible and mechanism-based 
inhibition of CYP3A (Figure 1). The “supratherapeutic” silibinin dose in the current study was 
selected to provide a large range between the predicted interaction based on reversible and 
mechanism-based inhibition of CYP3A and to maximize the ability to observe a clinical 
interaction. The lack of an interaction observed in all but one subject indicated that the CYP3A 
interaction liability for silibinin is low and is more consistent with reversible than mechanism-
based inhibition (assuming inhibition indeed occurred). The current work represents another 
example of a potential mechanism-based inhibitor identified in vitro16 that does not manifest 
clinically. 
Modeling and simulation of the silibinin–midazolam interaction indicated that the low 
interaction potential is due, in part, to the lower inhibition potency of the silibinin constituents 
toward CYP3A compared to CYP2C9 (Table 3). Ten-fold increases in inhibition potency of 
silybin A and silybin B toward CYP3A activity increased midazolam exposure by roughly 25% 
(Supplementary Figure S1 andSupplementary Materials and Methods). These observations 
indicated that at the predicted exposures, the constituents would need to be 10-fold more potent 
to demonstrate any clinically relevant interaction with CYP3A. The large predicted increase in 
midazolam exposure incorporating mechanism-based inhibition further supported the hypothesis 
that products with limited systemic exposure (first posited with fruit juices)25 need to be 
mechanism-based inhibitors of CYP enzymes to perpetrate clinically relevant interactions. 
Table 3 - Physiologically based pharmacokinetic model input parameters. 
 
 
One limitation to the current work is that silybin A and silybin B clearance parameters were 
recovered by fitting the model to data obtained from hepatitis C patients administered a product 
(silymarin) that contained additional constituents not present in silibinin.26 In vitro determination 
of silibinin clearance parameters would provide a true bottom-up modeling approach and reduce 
complexities inherent to pharmacokinetic data from patients with hepatic disease. Alternatively, 
disease-related parameters could be used to develop a hepatitis C virtual population before fitting 
the PBPK model with the observed pharmacokinetic data, facilitating recovery of disease-
independent silibinin clearance parameters.27,28,29 
In summary, prospective evaluation of herb–drug interactions, consistent with that for drug–drug 
interactions, largely has been ignored due to substantial compositional variability inherent to 
herbal products, multiple inhibitory constituents, varying inhibition mechanisms, and relative 
lack of regulatory oversight. The PBPK interaction model developed in the current work 
incorporatedin vitro inhibition kinetic parameters and systemic exposure estimates of individual 
constituents for the exemplar herbal product, silibinin. Simulations of the silibinin–warfarin and 
silibinin–midazolam interactions accurately predicted minimal clinical interaction liability. This 
work demonstrated the utility and predictive power of PBPK modeling and simulation, which 
could be extended to investigate scenarios (e.g., wide dosing ranges, tissue exposure assessment, 
and herbal product composition variation) and patient populations (e.g., pediatric, geriatric, and 
pregnant women) not amenable to clinical investigation. Refinement of the PBPK model by 
recovering disease-independent silibinin clearance parameters and incorporating alternate victim 
drugs, including losartan, will enhance confidence in model predictions and generalizability. 
This framework represents an initial step to establishing a systematic approach that can be 
applied to other combinations of herbal products and conventional drugs under various clinical 
scenarios to identify potential clinically significant herb–drug interactions, predict the extent of 
those interactions, and ultimately help guide pharmacotherapeutic decisions. 
METHODS 
PBPK model development. The base model structure was adapted from the literature30 (Figure 
4), incorporating physiologic parameters obtained from the International Commission on 
Radiological Protection.31 Warfarin partition coefficients (Kps)32 and binding parameters33 were 
obtained from the literature (Table 3); absorption rate constants (kas) and clearance parameters 
were obtained by fitting the PBPK model to previously reported plasma concentration–time 
profiles.20 The reversible inhibition constant (Ki) of (R)-warfarin toward CYP2C9 activity was 
obtained from the literature.34 Midazolam Kps and ka were obtained from the literature30,35; 
intestinal and hepatic clearance parameters were extrapolated from in vitro data16 as 
described36,37 (Table 3). Silybin A and silybin B Kps were predicted from physicochemical 
properties38 using GastroPlus (version 8.0; Simulations Plus, Lancaster, CA). Silibinin binding 
parameters were obtained from the literature39; clearance parameters were generated by fitting 
the PBPK model to plasma concentration–time data from hepatitis C patients receiving 
silymarin26 (Table 3). Silybin A and silybin B mechanism-based (KI,kinact) and reversible 
inhibition kinetic parameters were obtained from the literature.15,16 Mechanism-based inhibition 
of CYP2C9 was not considered based on a previous publication showing no IC50 shift using (S)-
warfarin as the probe substrate.15 
 
Figure 4.Base physiologically based pharmacokinetic model structure. Model structure was 
modified from the literature.30 Organ weights and blood flows were obtained from the 
International Commission on Radiological Protection.31 Following oral administration, drug 
transfer from dosing compartment to intestine is driven by the oral absorption rate constant (ka). 
Drug clearance (Cl) is mediated by metabolic processes in the intestine and liver. The pancreas 
and spleen were combined into a hybrid “organ” designated as PSP. 
PBPK interaction model simulations. PBPK models were developed for midazolam, (R)-
warfarin, (S)-warfarin, silybin A, and silybin B using Berkeley Madonna (version 8.3; University 
of California at Berkeley, Berkeley, CA) with code compiled in MEGen40 (version 0.5; UK 
Health & Safety Laboratory, Buxton, UK) (Supplementary Materials and Methods). The 
PBPK model for perpetrator (silybin A and silybin B) and victim (warfarin or midazolam) 
compounds were linked through the reversible or mechanism-based inhibition of victim probe 
substrate. Initial simulations used doses of probe substrates and milk thistle products reported in 
previous studies. Simulations were considered accurate if the predicted primary pharmacokinetic 
outcomes (AUC and Cmax for (S)-warfarin and midazolam) were within 30% of observed 
outcomes. Following initial model evaluation, simulations were conducted with a higher dose of 
silibinin (1,650 mg/day) to determine whether a clinically important interaction is possible. 
Pharmacokinetic outcomes from the simulated profiles were recovered via noncompartmental 
analysis using Phoenix WinNonlin (version 6.3; Pharsight, Cary, NC). 
Analysis of silibinin product. Siliphos capsules (n = 28) (Thorne Research, Dover, ID) were 
analyzed using a modification of previously described methods41,42 to ensure purity and content. 
Briefly, the contents of each capsule were weighed and extracted twice with 2 ml acetone. The 
extract was vortex mixed and centrifuged (13,000g for 2 minutes); the supernatant was 
transferred to a clean vial. Milk thistle constituents were quantified using an Acquity UPLC 
system with an HSS-T3 1.8 µm (2.1 × 100 mm) Acquity column and Empower 3 software 
(Waters, Milford, MA). Standards and Siliphos capsule extracts were analyzed using a gradient 
from 30:70 to 55:45 methanol:water (0.1% formic acid) over 5.0 minutes at a flow rate of 
0.6 ml/minute at 50 °C; peaks were detected at 288 nm. 
Proof-of-concept clinical study. Healthy volunteers (six men and six nonpregnant women) were 
enrolled in an open-label, fixed sequence crossover study conducted at the UNC CTRC. The 
study protocol was approved by the UNC Office of Human Research Ethics Biomedical 
Institutional Review Board and the CTRC Advisory Committee. Eligibility to participate was 
based on screening evaluation and inclusion/exclusion criteria (Supplementary Table S1). 
Written informed consent was obtained from each subject prior to enrollment. 
The first (control) phase consisted of administration of 10 mg warfarin (Coumadin; Bristol 
Meyers Squibb, Princeton, NJ), 10 mg vitamin K (Mephyton; Aton Pharma, Lawrenceville, NJ), 
and 5 mg midazolam syrup (Ranbaxy; Jacksonville, FL). A negative pregnancy result was 
required before drug administration to women of childbearing potential. Vital signs (blood 
pressure, temperature, respiratory rate, pulse, and oxygen saturation) were obtained at baseline 
and every 15 minutes for the first 2 hours. All subjects underwent an international normalized 
ratio with prothrombin time. Blood (7 ml) was collected through an intravenous line before and 
from 0.25–12 hours following drug administration. Subjects continued to fast until after the 4-
hour blood collection, when meals and snacks, devoid of fruit juices and caffeinated beverages, 
were provided. Subjects returned to the CTRC 24 and 48 hours post-drug administration for 
blood collection. Optimal study design simulations43 of previously reported clinical 
data20 demonstrated that a 0–48-hour collection was an accurate surrogate of total systemic 
exposure (AUC0–inf) for warfarin. Plasma was collected and stored at −80 °C pending analysis by 
high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS). 
Following at least a 14-day washout, subjects received 480 mg silibinin (based on labeled 
content) to self-administer three times daily for 7 days. Each subject received his/her silibinin in 
a blister pack and was asked to complete a pill diary documenting the time of administration. 
Subjects were contacted at least twice during the week of silibinin self-administration to monitor 
compliance and adverse events, which were graded using a validated Adverse Events Scale. 
Subjects returned to the CTRC on day 7 for concomitant administration of silibinin, warfarin, 
vitamin K, and midazolam. Plasma was collected and stored as described for the first phase. 
Analysis of plasma for warfarin enantiomers, midazolam, silybin A, and silybin B.Concentrations 
of all analytes were quantified using a Sciex (Framingham, MA) API4000 Qtrap HPLC-MS/MS 
triple quadrupole mass spectrometer fitted with a Turbo ionspray interface operated in the 
positive ion mode. Plasma was treated with acetonitrile (6 volumes) containing the internal 
standard, warfarin-d5(Toronto Research Chemicals; Toronto, Canada) or 1′-hydroxymidazolam-
d4(Cerilliant, Round Rock, TX), and centrifuged (3,000g). The supernatant was injected into the 
HPLC-MS/MS system. Warfarin enantiomers were separated on a Supelco Astec Chirobiotic V 
15 cm × 2.1 mm 5 micron chiral column (Sigma Aldrich; St Louis, MO) and eluted with an 
isocratic mixture consisting of 75% 5 mmol/l ammonium acetate containing 0.01% (v/v) formic 
acid and 25% acetonitrile (flow rate, 0.4 ml/minute). Midazolam was eluted with a binary 
gradient mixture consisting of 10 mmol/l ammonium formate containing 1% (v/v) isopropyl 
alcohol and 0.1% (v/v) formic acid and methanol on a Varian Polaris C18-A 20 cm × 2.0 mm 5 
micron column (Agilent, Santa Clara, CA) (flow rate, 0.65 ml/minute). Silybin A and silybin B 
were eluted with an isocratic mixture consisting of 44% water, 56% methanol, and 0.1% (v/v) 
formic acid on an Agilent Zorbax XDB C18 15 cm × 3.0 mm 3.5 micron column (Agilent) (flow 
rate, 0.7 ml/minute). Analyte concentrations were determined by interpolation from a linear 
standard curve with an assay dynamic range of 0.5–10,000 nmol/l (warfarin enantiomers) or 0.5–
5,000 nmol/l (midazolam, silybin A, silybin B). Analytical methods were validated according to 
US Food and Drug Administration guidelines.44 Inter- and intraday variability for all analytes 
was less than 10%. 
Pharmacokinetic analysis. Pharmacokinetic outcomes were recovered by noncompartmental 
analysis using Phoenix WinNonlin. Concentrations below the limit of quantification were 
excluded. The terminal elimination rate constant (λz) was estimated by linear regression of the 
terminal portion of the log-transformed concentration–time profile using at least three data 
points. The terminal half-life (t1/2) was calculated as ln2/λz. The maximum observed 
concentration (Cmax), time to reach Cmax (tmax), and last measured concentration (Clast) were 
obtained directly from the concentration–time profile. AUC from time zero to Clast (AUC0–last) 
was determined using the trapezoidal method with linear up/log down interpolation. The AUC 
from time zero to infinity (AUC0–inf) was calculated as the sum of AUC0–last and the ratio 
of Clast to λz. 
Genotyping for common CYP2C9 variants. CYP2C9*2 and *3 polymorphisms were determined 
using a previously published polymerase chain reaction restriction fragment length 
polymorphism assay.45 
Statistical analysis. All statistical analyses were conducted using SAS (version 9.2; SAS 
Institute, Cary, NC). The sample size for the proof-of-concept study (n= 12 evaluable subjects) 
was calculated based on 80% power to detect a 25% change in the primary endpoints with a type 
I error of 0.05; the primary endpoints were the treatment/control ratios of log-transformed AUC0–
48 ((S)-warfarin) or AUC0–inf (midazolam) and Cmax ((S)-warfarin and midazolam), and the 
predefined no effect range was 0.75–1.33.5,6 Intraindividual variability in midazolam and 
warfarin AUC and Cmax were assumed to be ~20%.46,47,48 Secondary outcomes,t1/2 and tmax, were 
evaluated using a paired two-tailed Student’s t-test on log-transformed data or Wilcoxon signed-
rank test as appropriate, with 90% confidence intervals and ranges reported for t1/2 and tmax, 
respectively. A Pvalue <0.05 was considered statistically significant. 
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